[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
January 10, 2001

Nonresponse to Interferon in Chronic Hepatitis CRe-treatment Redux

Author Affiliations

Author Affiliation: Department of Medicine, Division of Digestive Disease and Nutrition, University of Massachusetts, Memorial Health Care, Worcester.

JAMA. 2001;285(2):212-214. doi:10.1001/jama.285.2.212

In the past decade, chronic hepatitis due to hepatitis C virus (HCV) infection has emerged as the predominant liver disease in the United States. While progression of chronic hepatitis C to cirrhosis may be slow, end-stage liver disease due to HCV-associated cirrhosis is now the single most common indication for liver transplantation, and HCV-associated cirrhosis is responsible for the increasing incidence of hepatocellular carcinoma in this country.1 Direct costs of care for patients with progressive disease are high, treatment is expensive, and the national economic burden of hepatitis C has been projected to increase dramatically in the future.2 Fortunately, progress in antiviral treatment has been steady and impressive.

First Page Preview View Large
First page PDF preview
First page PDF preview
×